Millennium Management LLC Decreases Position in Marinus Pharmaceuticals Inc (MRNS)

Millennium Management LLC cut its stake in shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 72.9% during the 2nd quarter, Holdings Channel reports. The firm owned 156,930 shares of the biopharmaceutical company’s stock after selling 422,209 shares during the period. Millennium Management LLC’s holdings in Marinus Pharmaceuticals were worth $1,109,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Trexquant Investment LP bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $102,000. GSA Capital Partners LLP bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $141,000. Rhumbline Advisers bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $245,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $363,000. Finally, Alps Advisors Inc. bought a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $416,000. 63.68% of the stock is currently owned by institutional investors.

NASDAQ:MRNS opened at $5.46 on Friday. Marinus Pharmaceuticals Inc has a one year low of $3.31 and a one year high of $10.54. The company has a market cap of $221.27 million, a P/E ratio of -6.83 and a beta of 3.20.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Monday, October 29th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.06). Analysts predict that Marinus Pharmaceuticals Inc will post -0.88 earnings per share for the current year.

Several brokerages recently issued reports on MRNS. Mizuho reaffirmed a “buy” rating and set a $13.00 price target on shares of Marinus Pharmaceuticals in a report on Tuesday, September 25th. Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. BidaskClub raised shares of Marinus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 20th. ValuEngine lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 6th. Finally, Zacks Investment Research upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 10th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Marinus Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $19.67.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

See Also: Earnings Per Share (EPS)

Want to see what other hedge funds are holding MRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marinus Pharmaceuticals Inc (NASDAQ:MRNS).

Institutional Ownership by Quarter for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply